Treatment with sulforaphane (SFN), an Nrf2 activator, in a pulmonary fibrosis mouse model, attenuated alveolitis, fibrosis, apoptosis and lung oxidative stress by increasing the expression of antioxidant enzymes, including NAPDH, Nqo1, Ho1, superoxide dismutase and catalase [11]. This evidence concerns the gene NFE2L2 and pulmonary fibrosis.